Switch theme
Sign up to access all valuation multiples
Jiangxi Fushine Pharmaceutical Co Ltd is engaged in research and development, manufactures and sells APIs and pharmaceutical intermediates. It offers penicillin, carbapenem, and other products.
2002
n/a
Last FY Revenue $163M
Last FY EBITDA -$10.7M
$867M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Jiangxi Fushine Pharma Co achieved revenue of $163M and an EBITDA of -$10.7M.
Jiangxi Fushine Pharma Co expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangxi Fushine Pharma Co valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $163M | XXX | XXX | XXX |
| Gross Profit | XXX | $15.8M | XXX | XXX | XXX |
| Gross Margin | XXX | 10% | XXX | XXX | XXX |
| EBITDA | XXX | -$10.7M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -7% | XXX | XXX | XXX |
| EBIT | XXX | -$12.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | -8% | XXX | XXX | XXX |
| Net Profit | XXX | -$37.8M | XXX | XXX | XXX |
| Net Margin | XXX | -23% | XXX | XXX | XXX |
| Net Debt | XXX | $82.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jiangxi Fushine Pharma Co's stock price is CNY 10 (or $1).
Jiangxi Fushine Pharma Co has current market cap of CNY 5.2B (or $728M), and EV of CNY 6.2B (or $867M).
See Jiangxi Fushine Pharma Co trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $867M | $728M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jiangxi Fushine Pharma Co has market cap of $728M and EV of $867M.
Jiangxi Fushine Pharma Co's trades at 5.3x EV/Revenue multiple, and -81.3x EV/EBITDA.
Equity research analysts estimate Jiangxi Fushine Pharma Co's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangxi Fushine Pharma Co's P/E ratio is not available.
See valuation multiples for Jiangxi Fushine Pharma Co and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $728M | XXX | $728M | XXX | XXX | XXX |
| EV (current) | $867M | XXX | $867M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 5.3x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -81.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -70.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -19.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 136.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJiangxi Fushine Pharma Co's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Jiangxi Fushine Pharma Co's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangxi Fushine Pharma Co's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jiangxi Fushine Pharma Co and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -7% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Race Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Ascentage Pharma Group | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Actuate Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangxi Fushine Pharma Co acquired XXX companies to date.
Last acquisition by Jiangxi Fushine Pharma Co was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangxi Fushine Pharma Co acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jiangxi Fushine Pharma Co founded? | Jiangxi Fushine Pharma Co was founded in 2002. |
| Where is Jiangxi Fushine Pharma Co headquartered? | Jiangxi Fushine Pharma Co is headquartered in China. |
| Is Jiangxi Fushine Pharma Co publicy listed? | Yes, Jiangxi Fushine Pharma Co is a public company listed on SHE. |
| What is the stock symbol of Jiangxi Fushine Pharma Co? | Jiangxi Fushine Pharma Co trades under 300497 ticker. |
| When did Jiangxi Fushine Pharma Co go public? | Jiangxi Fushine Pharma Co went public in 2015. |
| Who are competitors of Jiangxi Fushine Pharma Co? | Similar companies to Jiangxi Fushine Pharma Co include e.g. Race Oncology, Supriya Lifescience, Ascentage Pharma Group, ST Pharm. |
| What is the current market cap of Jiangxi Fushine Pharma Co? | Jiangxi Fushine Pharma Co's current market cap is $728M |
| Is Jiangxi Fushine Pharma Co profitable? | Yes, Jiangxi Fushine Pharma Co is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
